Edition:
United States

Zosano Pharma Corp (ZSAN.OQ)

ZSAN.OQ on NASDAQ Stock Exchange Capital Market

4.20USD
25 Apr 2018
Change (% chg)

$0.02 (+0.48%)
Prev Close
$4.18
Open
$4.15
Day's High
$4.20
Day's Low
$4.06
Volume
45,051
Avg. Vol
232,162
52-wk High
$35.40
52-wk Low
$3.63

Chart for

About

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved... (more)

Overall

Beta: --
Market Cap(Mil.): $49.57
Shares Outstanding(Mil.): 11.97
Dividend: --
Yield (%): --

Financials

  ZSAN.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -18.14 -- --
ROI: -312.45 -0.73 12.97
ROE: -504.73 -2.77 14.84

BRIEF-Zosano Announces Pricing Of 10 Mln Common Shares At $5 per Share

* ZOSANO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Mar 29 2018

BRIEF-Zosano Pharma Corp Files For Offering 10 Mln Shares Of Co's Common Stock‍​

* ZOSANO PHARMA CORP FILES FOR OFFERING 10 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING‍​ Source text: [https://bit.ly/2J2rCA6] Further company coverage:

Mar 28 2018

BRIEF-Zosano Pharma Corp Files ‍Prospectus Related To Offering Of 3.23 mln Shares Co's Common Stock

* ZOSANO PHARMA CORP FILES PROSPECTUS RELATED TO OFFERING OF 3.23 MILLION SHARES CO'S COMMON STOCK - SEC FILING​ Source text - https://bit.ly/2pFJlFL Further company coverage:

Mar 26 2018

BRIEF-Zosano Reaches Enrollment Milestone In M207-Adam Long-Term Safety Study

* ZOSANO REACHES ENROLLMENT MILESTONE IN M207-ADAM LONG-TERM SAFETY STUDY

Mar 16 2018

BRIEF-Zosano Pharma Reports Q4 Loss Per Share $3.80

* ZOSANO PHARMA REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL UPDATE

Mar 12 2018

BRIEF-Zosano Pharma Announces Issuance Of New U.S. Patent Covering M207 As An Acute Treatment For Migraine

* ZOSANO PHARMA ANNOUNCES ISSUANCE OF NEW U.S. PATENT COVERING M207 AS AN ACUTE TREATMENT FOR MIGRAINE Source text for Eikon: Further company coverage:

Mar 02 2018

BRIEF-Zosano Pharma Files Prospectus Related Offering 12.5 Mln Shares

* ZOSANO PHARMA CORP FILES PROSPECTUS RELATED OFFERING 12.5 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING Source text: (http://bit.ly/2EDTBag) Further company coverage:

Feb 13 2018

BRIEF-Zosano Pharma Files Prospectus Related To 10 Mln Stock Offering

* ZOSANO PHARMA CORP FILES PROSPECTUS RELATED TO OFFERING 10 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING‍​ Source text (http://bit.ly/2GUOzEr) Further company coverage:

Feb 06 2018

BRIEF-Zosano Pharma Files For Offering Of Up To $57.5 Million Shares

* ZOSANO PHARMA FILES FOR OFFERING OF UP TO $57.5 MILLION SHARES - SEC FILING Source text :[http://bit.ly/2BPJFqj] Further company coverage:

Dec 22 2017

BRIEF-Zosano Pharma Says Board To Reduce Size To Five

* ZOSANO PHARMA SAYS BOARD OF DIRECTORS ADOPTED A RESOLUTION TO REDUCE SIZE OF BOARD TO FIVE DIRECTORS - SEC FILING Source: (http://bit.ly/2j7YwDM) Further company coverage:

Dec 15 2017

Earnings vs. Estimates